60 studies found for:    gene expression | Open Studies | Interventional Studies | breast cancer | Phase 2, 3
Show Display Options
Rank Status Study
21 Recruiting Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence
Condition: HER2 Low to Intermediate Breast Cancer
Interventions: Biological: NeuVax™ vaccine;   Biological: Leukine® (sargramostim, GM-CSF) and water for injection
22 Recruiting 18F FPPRGD2 Positron Emission Tomography/Computed Tomography in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Male Breast Cancer;   Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma;   Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Adult Brain Tumor;   Recurrent Basal Cell Carcinoma of the Lip;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity;   Recurrent Hypopharyngeal Cancer;   Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Laryngeal Cancer;   Recurrent Lip and Oral Cavity Cancer;   Recurrent Lymphoepithelioma of the Nasopharynx;   Recurrent Lymphoepithelioma of the Oropharynx;   Recurrent Metastatic Squamous Neck Cancer With Occult Primary;   Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity;   Recurrent Mucoepidermoid Carcinoma of the Oral Cavity;   Recurrent Nasopharyngeal Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Oropharyngeal Cancer;   Recurrent Pancreatic Cancer;   Recurrent Paranasal Sinus and Nasal Cavity Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Salivary Gland Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVA Salivary Gland Cancer;   Stage IVB Colon Cancer;   Stage IVB Salivary Gland Cancer;   Stage IVC Salivary Gland Cancer;   Tongue Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Radiation: fludeoxyglucose F 18;   Radiation: 2-fluoropropionyl-labeled pegylated dimeric RGD peptide;   Procedure: positron emission tomography;   Procedure: computed tomography;   Other: laboratory biomarker analysis
23 Recruiting Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Drug: doxorubicin hydrochloride;   Other: laboratory biomarker analysis
24 Recruiting Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer
Condition: Operable Breast Cancer
Intervention: Drug: 0.5% lignocaine 60mM
25 Recruiting Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Condition: Metastatic Breast Cancer
Intervention: Drug: Orteronel
26 Recruiting A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Metformin;   Drug: Placebo
27 Recruiting A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel
28 Not yet recruiting The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: gefitinib
29 Recruiting ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer
Conditions: Breast Cancer;   Breast Disease;   Neoplasms;   Neoplasms by Site
Intervention: Drug: cyclophosphamide, Adriamycin, Docetaxel, Trastuzumab, Zolendronic acid
30 Recruiting A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)
Condition: Early Breast Cancer
Interventions: Drug: LEE011;   Drug: Letrozole
31 Recruiting A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU)
Conditions: Head and Neck Neoplasms;   Lung Neoplasms;   Urinary Bladder Neoplasms;   Breast Neoplasms
Interventions: Drug: 5-Fluoro-2-Deoxycytidine (FdCyd);   Drug: Tetrahydrouridine (THU)
32 Recruiting Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
Condition: Breast Cancer
Interventions: Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
33 Recruiting Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Condition: Breast Cancer
Intervention: Drug: Dasatinib and Paclitaxel
34 Recruiting AR and ER Imaging in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Other: FDHT-PET scan;   Other: FES-PET scan;   Other: CT-scan;   Other: Bone scintigraphy;   Other: Tumor biopsy
35 Recruiting Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Anastrozole;   Drug: Anastrozole+Fulvestrant;   Drug: Tamoxifen
36 Recruiting Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Temsirolimus plus Neratinib
37 Recruiting Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Drug: BKM120 + lapatinib
38 Not yet recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
39 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
40 Recruiting Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Biological: trastuzumab;   Other: placebo;   Biological: polysaccharide-K;   Other: laboratory biomarker analysis

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years